Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer and Low Risk for Local Failure: A Randomized Phase III Trial of the German Rectal Cancer Study Group

NCT04495088 is registered in ClinicalTrials.gov with Ralf Hofheinz as lead sponsor.

NCT NCT04495088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04495088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer and Low Risk for Local Failure: A Randomized Phase III Trial of the German Rectal Cancer Study Group
Lead sponsor
Ralf Hofheinz
Phase
Phase 3
Overall status
Terminated
Start date
September 30, 2020
Completion date
July 31, 2026
Enrollment
215 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer